The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results

Basra, M. K. A.; Fenech, R.; Gatt, Ruben; Salek, Mir-saeed; Finlay, A.Y.

doi:10.1111/j.1365-2133.2008.08832.x

Cited by 569 publications

(790 citation statements)

References 247 publications

Supporting

Mentioning

715

Contrasting

Unclassified

Order By: Relevance

“…Daily UAS values (0-6 points) were calculated on the patient's conditions over the previous 24 hours, by adding the score value for number of wheals (0-3) and for pruritus intensity (0-3), as already described (10). Patients quality of life was evaluated at baseline by Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL) and other metrics commonly used in clinical practice (Visual Analogic Scale, VAS; Dermatology Life Quality Index, DLQI) (1,(10)(11)(12)(13)(14).…”

Section: Disease Activity and Quality Of Life Assessmentmentioning

confidence: 99%

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Berti

Yacoub

Skov

et al. 2017

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

Section: Disease Activity and Quality Of Life Assessmentmentioning

confidence: 99%

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Berti

Yacoub

Skov

et al. 2017

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

“…The DLQI consists of 10 items and the total score ranges from 0 to 30; a score of 0 or 1 indicates no effect (of the skin condition) on the patient's life, while a score of 21–30 indicates an extremely large effect on the patient's life. The minimal clinically important difference for the DLQI has been estimated as a 2‐ to 5‐point change from baseline;25 here, a minimal clinically important difference of ≥ 5‐point change from baseline is used.…”

Section: Methodsmentioning

confidence: 99%

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Griffiths

Vender

Sofen

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis.ObjectivesTo describe the effects of tofacitinib withdrawal/re‐treatment on health‐related quality of life (HRQoL) and disease symptoms measured by patient‐reported outcomes (PROs).MethodsThe study was divided into initial treatment, treatment withdrawal, and re‐treatment periods. Initial treatment: patients were randomized to receive tofacitinib 5 (n = 331) or 10 mg (n = 335) BID for 24 weeks. Treatment withdrawal: patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI) score from baseline and Physician's Global Assessment of ‘clear’/‘almost clear’ at Week (W)24 received placebo (withdrawal) or the previous dose (continuous treatment). Re‐treatment: at relapse (> 50% loss of W24 PASI response) or at W40, patients received their initial tofacitinib dose. PROs included: Dermatology Life Quality Index (DLQI), Itch Severity Item (ISI), Short Form‐36 (SF‐36) and Patient's Global Assessment (PtGA).ResultsAfter initial treatment with tofacitinib 5 and 10 mg BID, substantial and significant improvements were reported for mean DLQI (baseline: 12.6 and 12.6; W24: 5.1 and 2.6) and ISI (baseline: 6.7 and 6.9; W24: 2.9 and 1.6). Patients continuously treated with tofacitinib 5 and 10 mg BID maintained those improvements through Week 56 (DLQI: 3.0 and 2.1; ISI: 2.3 and 1.4). By W40, patients withdrawn from tofacitinib 5 and 10 mg BID showed worsening in DLQI (5.0 and 6.2) and ISI (3.7 and 4.0) scores; improvements were regained upon re‐treatment (W56, DLQI: 3.4 and 2.4; ISI: 2.2 and 1.6). Similar results were reported for PtGA and SF‐36.ConclusionContinuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re‐treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.

show abstract

“…Successivamente, ciascun paziente è stato invitato a disegnare il proprio "albero della soddisfazione", scrivendo su post-it (le foglie dell'albero) le caratteristiche della terapia ideale a suo giudizio. Conclusa questa fase, i concetti emersi sono stati ripresi nell'analisi di due questionari validati comunemente impiegati negli studi clinici sulla psoriasi, il DLQI [20] e il TSQM [21], con lo scopo di elaborare una sintesi tra queste due misure di PRO e gli aspetti della malattia -la quale impone esigenze specifiche costringendoli a modificare le attività quotidiane e ad alterarne il ritmo -e l'umore depresso. I pazienti hanno inoltre espresso la propria frustrazione per dover accettare una situazione incontrollabile a causa di terapie inefficaci (o che lo diventano), con conseguente riacutizzazione dei sintomi.…”

Section: Metodologia DI Lavorounclassified

Patients engagemnet in clinical trial input

Malagoli

2016

ABTPN

View full text Add to dashboard Cite

IntroduzioneLa psoriasi, della quale soffrono circa 1.500.000 persone nel nostro Paese (corrispondenti a una prevalenza del 2,8%), è tradizionalmente considerata una malattia infiammatoria della cute, nonostante il dimostrato coinvolgimento sistemico possa determinare un ampio ventaglio di comorbilità a carico di altri organi/apparati [1,2]. La forma più frequente è la psoriasi a placche (80-90% dei casi), caratterizzata dalla comparsa di placche eritemato-squamose localizzate su cuoio capelluto, tronco e arti, spesso associate a prurito, dolore e secchezza della cute, che può arrivare a lacerarsi e a sanguinare [1,3]. La psoriasi guttata, la psoriasi eritrodermica e la psoriasi pustolosa costituiscono delle varianti della malattia distinte per morfologia e andamento. Nel 33% circa dei pazienti psoriasici si osservano alterazioni distrofiche delle unghie [1]. Inoltre, nel 20-30% circa dei casi, generalmente alcuni anni dopo l'insorgenza delle lesioni cutanee, si hanno manifestazioni articolari diagnosticabili come artrite psoriasica, una malattia spesso trascurata e/o sottodiagnosticata [4][5][6]. La psoriasi può insorgere a ogni età, ma ci sono due picchi di presentazione, il primo tra i 15 e i 20 anni e il secondo tra i 55 e i 60 [7]. Il suo andamento è cronico-recidivante: i pazienti -che non raggiungono mai la guarigione -sperimentano periodi nei quali la malattia è meno evidente alternati a periodi di riacutizzazione [7]. Nella patogenesi della psoriasi, non ancora completamente chiarita, si riconosce una complessa base genetica sulla quale intervengono vari fattori ambientali tra cui l'impiego di farmaci, i traumi cutanei, le infezioni e lo stress. Inoltre, crescenti evidenze indicano il coinvolgimento di meccanismi immunologici, con la risoluzione della psoriasi associata a Patient engagement in clinical trial input. La valutazione del trattamento della psoriasi dal punto di vista del paziente

show abstract

The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results

Cited by 569 publications

References 247 publications

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Patients engagemnet in clinical trial input

Contact Info

Product

Resources

About